Patents by Inventor Wilma Tamraz
Wilma Tamraz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220280646Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.Type: ApplicationFiled: February 14, 2022Publication date: September 8, 2022Applicant: DURECT CORPORATIONInventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks Boyd, Christopher M. RUBINO
-
Patent number: 11285217Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.Type: GrantFiled: June 1, 2020Date of Patent: March 29, 2022Assignee: Durect CorporationInventors: Jeremy C. Wright, Wilma Tamraz, John J. Leonard, John W. Gibson, Keith E. Branham, Stefania Sjobeck, Brooks Boyd, Christopher M. Rubino
-
Publication number: 20210169902Abstract: Methods of treating and prophylactically treating inflammatory skin diseases and skin lesions are provided. For instance, the methods may involve contacting the skin with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 16, 2020Publication date: June 10, 2021Inventors: Shunlin Ren, WeiQi Lin, James E. Brown, Felix Theeuwes, Mee Jean Kim, Andrew R. Miksztal, Hongwei Wu, Min L. Lee, Huey-Ching Su, Wilma Tamraz
-
Publication number: 20210169898Abstract: Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.Type: ApplicationFiled: November 10, 2020Publication date: June 10, 2021Inventors: Shunlin Ren, Leyuan Xu, Yanxia Ning, Jin Koung Kim, WeiQi Lin, Mee Jean Kim, Andrew R. Miksztal, Hongwei Wu, Min L. Lee, Wilma Tamraz
-
Publication number: 20210015924Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic- acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.Type: ApplicationFiled: June 1, 2020Publication date: January 21, 2021Applicant: DURECT CORPORATIONInventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks Boyd, Christopher M. RUBINO
-
Publication number: 20200383957Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: ApplicationFiled: May 19, 2020Publication date: December 10, 2020Applicants: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
-
Publication number: 20200352852Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: ApplicationFiled: April 27, 2020Publication date: November 12, 2020Applicants: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
-
Patent number: 10682340Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: GrantFiled: December 28, 2017Date of Patent: June 16, 2020Assignees: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma Tamraz, Huey-Ching Su, WeiQi Lin, Kazuhito Yamada, Naoki Matsumoto, Sreenivasu Mudumba, Komei Okabe
-
Patent number: 10668011Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: GrantFiled: June 29, 2017Date of Patent: June 2, 2020Assignees: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma Tamraz, Huey-Ching Su, WeiQi Lin, Kazuhito Yamada, Naoki Matsumoto, Sreenivasu Mudumba, Komei Okabe
-
Publication number: 20200085829Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.Type: ApplicationFiled: August 19, 2019Publication date: March 19, 2020Applicant: DURECT CORPORATIONInventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks BOYD, Christopher M. RUBINO
-
Publication number: 20190374554Abstract: Methods of treating and prophylactically treating inflammatory skin diseases and skin lesions are provided. For instance, the methods may involve contacting the skin with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 1, 2017Publication date: December 12, 2019Inventors: Shunlin Ren, WeiQi Lin, James E. Brown, Felix Theeuwes, Mee Jean Kim, Andrew R. Miksztal, Hongwei Wu, Min L. Lee, Huey-Ching Su, Wilma Tamraz
-
Publication number: 20190269695Abstract: Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.Type: ApplicationFiled: August 1, 2017Publication date: September 5, 2019Inventors: Shunlin Ren, Leyuan Xu, Yanxia Ning, Jin Koung Kim, WeiQi Lin, Mee Jean Kim, Andrew R. Miksztal, Hongwei Wu, Min L. Lee, Wilma Tamraz
-
Publication number: 20190255179Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.Type: ApplicationFiled: January 17, 2019Publication date: August 22, 2019Applicant: DURECT CORPORATIONInventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks Boyd, Christopher M. RUBINO
-
Patent number: 10226532Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.Type: GrantFiled: July 18, 2017Date of Patent: March 12, 2019Assignee: DURECT CORPORATIONInventors: Jeremy C. Wright, Wilma Tamraz, John J. Leonard, John W. Gibson, Keith E. Branham, Stefania Sjobeck, Brooks Boyd, Christopher M. Rubino
-
Publication number: 20180140605Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.Type: ApplicationFiled: January 16, 2018Publication date: May 24, 2018Applicant: DURECT CORPORATIONInventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks BOYD, Christopher M. RUBINO
-
Publication number: 20180117016Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: ApplicationFiled: December 28, 2017Publication date: May 3, 2018Applicants: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
-
Publication number: 20180036412Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.Type: ApplicationFiled: July 18, 2017Publication date: February 8, 2018Applicant: DURECT CORPORATIONInventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks Boyd, Christopher M. RUBINO
-
Publication number: 20180000729Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: ApplicationFiled: June 29, 2017Publication date: January 4, 2018Applicants: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
-
Patent number: 9737605Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.Type: GrantFiled: March 11, 2014Date of Patent: August 22, 2017Assignee: DURECT CORPORATIONInventors: Jeremy C. Wright, Wilma Tamraz, John J. Leonard, John W. Gibson, Keith E. Branham, Stefania Sjobeck, Brooks Boyd, Christopher M. Rubino
-
Publication number: 20170143721Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.Type: ApplicationFiled: January 5, 2017Publication date: May 25, 2017Applicants: DURECT CORPORATION, ZOGENIX INC.Inventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks BOYD, Christopher M. RUBINO